UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39852 Scilex Holding Company (Exact Name of Registrant as Specified in Its Charter) Delaware 92-1062542 (State or Other Jurisdiction of Incorp ...

PALO ALTO, Calif., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, "Scilex" or the "Company"), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced a Master Distributor Agreement with Devart Middle East Food Supplements ("Devart Middle East"), as Master Distributor, and CH Trading Group LLC ("CH Trading Group"), as Territories Distributor, to expan ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________ FORM 8-K _______________________ CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 31, 2024 _______________________ | --- | --- | |---------------------------------------------------------------------------------------|---------------------------------| | | | | SCILEX HOLDING COMPANY (Exact name of registrant as ___________ ...

Core Insights - Scilex Holding Company has released its inaugural sustainability report, emphasizing its commitment to environmental stewardship, social responsibility, and governance practices [1][2][3] Environmental Stewardship - The company is dedicated to reducing its environmental footprint, recognizing the global impact of environmental health on everyone [2] Development Excellence - Scilex focuses on developing innovative non-opioid pain management products to address significant unmet medical needs, aiming to improve patient lives [2][3] Social Responsibility - The company emphasizes ethical business practices, respecting employee rights, and fostering an inclusive environment for its workforce and supply chain [2][3] Governance - Scilex promotes transparent corporate governance to ensure accountability and balance the interests of its stakeholders, including patients, suppliers, and employees [2] Strategic Focus - The company's strategy includes advancing patient health, expanding access to non-opioid pain management products, and investing in scientific excellence to expedite the availability of medicines [3]

PALO ALTO, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, "Scilex" or the "Company"), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced the release of its inaugural sustainability report which highlights sustainability efforts by the company related to its environmental footprint, contributing positively to society, and improving access ...

PALO ALTO, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, "Scilex" or the "Company"), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that its Chief Executive Officer and President, Jaisim Shah, and Executive Chairman, Henry Ji, Ph.D., will ring the Closing Bell at the Nasdaq MarketSite in Times Square, New York, at 4:00 p.m. Eastern ...

The ceremony will be held in celebration of Scilex's launch of GLOPERBA®, an innovative non-opioid product and the first oral liquid medicine for prophylactic treatment of painful gout flares. PALO ALTO, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, "Scilex" or the "Company"), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that its ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________ FORM 8-K _______________________ CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 1, 2024 _______________________ • ZTlido net sales for the month ended June 30, 2024 were in the range of $7.5 million to $9.0 million, compared to $4.4 million for the same period last year, representing growth in the range of approximately ...

Investors and Media Scilex Holding Company 960 San Antonio Road Palo Alto, CA 94303 Office: (650) 516-4310 ZTlido® net sales for the month of June 2024 grew in the range of 70% to 104%, compared to the same period last year. ZTlido® net sales for the quarter ended June 2024 grew in the range of 28% to 42%, compared to the same period last year. Total product net sales for the month of June 2024 grew in the range of 77% to 116%, compared to the same period last year. Total product net sales for the quarter e ...

PALO ALTO, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, "Scilex" or the "Company"), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that in anticipation of selling our commercially available products to new and current special customers, Scilex has entered into a non-exclusive distribution agreement with a well-known and highly resp ...